Metformin is a biguanide widely prescribed as an antidiabetic drug for type 2 diabetes mellitus patients. The purpose of the present study was to observe the effects of the new metformin derivative, HL156A, on human oral cancer cell and to investigate its possible mechanisms. It was observed that HL156A significantly decreased FaDu and YD-10B cell viability and colony formation in a dose-dependent way.
However, the precise mechanism for the multiple anticancer effects of metformin remains to be elucidated. Additionally, despite possessing many outstanding properties, limited cell penetration capacity as a result of its hydrophilic nature makes metformin unable to meet the requirements for use as an anticancer drug.
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HL156A is a derivative of metformin synthesized from pyrrolidine that is capable of inducing AMPK activation. It was reported that HL156A has protective effects against peritoneal and liver fibrosis. 14, 15 It was also reported that HL156A inhibited LPS-induced inflammation of macrophages. In addition, HL156A inhibits not only smad3-dependent signaling activated by high glucose conditions but also epithelial-mesenchymal transition (EMT). 15 A recent study showed that HL156A in combination with temozolomide inhibited the invasive properties of glioblastoma and increased the survival rate in a xenograft in vivo model. 16 In the present study, the effects of HL156A on the progression of oral cancer cells were examined. Our results suggest the potential abilities of the new metformin derivative HL156A as a candidate for a therapeutic modality for the treatment of oral cancer.
| MATERIALS AND METHODS

| Cell culture and reagents
For an OSCC cell line, FaDu, YD-10B, and AT64 cells were purchased from Korea Cell Line Bank (KCLB, Seoul, Korea). Human hypopharyngeal squamous cell carcinoma (FaDu) cells were maintained in a complete DMEM (Welgene Inc., Gyeongsanbuk-do, Korea), containing 10% FBS, 100 units/mL penicillin and 100 lg/ mL streptomycin. Human oral squamous cell carcinoma (YD-10B) and mouse oral squamous cell carcinoma (AT84) cells were cultured in RPMI-1640 medium containing 10% FBS, 100 U/mL penicillin, and 100 lg/mL streptomycin. The cells were maintained at 37°C in a humidified 5% CO 2 /95% air atmosphere. HL156A is a derivative of phenyl biguanide, which is designed and synthesized by Hanall Biopharma Inc. (Seoul, Korea). The detailed procedure of HL156A synthesis and structure was described in a previous study. 
| Soft agar colony formation assay
Briefly, cells (1 9 10 4 cells) were exposed to different concentrations of HL156A in 1 mL of 0.3% basal medium Eagle's agar containing 10% FBS and were plated in 60-mm plates containing 0.6% lowmelting temperature agarose. The cells were allowed to form colonies for 14 days at 37°C in a humidified atmosphere containing 5% CO 2 . The colonies were fixed with 4% paraformaldehyde for 30 min at room temperature and were then stained with 0.04% crystal violet for 30 min at room temperature. The cell colonies were scored using an IX2-SLP inverted microscope (Olympus, Tokyo, Japan).
| Annexin V-FITC/propidium iodide (PI) double staining and cell cycle analysis
Cell cycle distribution was analyzed using flow cytometry. Briefly, 
| Western blot analysis
Total protein from the cells was obtained using RIPA buffer (50 mmol/L Tris-Cl (pH 7.5), 150 mmol/L NaCl, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS and 1 mmol/L EDTA) containing a protease inhibitor cocktail (1 lg/mL aprotinin and leupeptin). Cell lysates (30 lg) were subjected to SDS-PAGE and then transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). The membranes were blocked with 5% skim milk for 1 hours and incubated with the primary antibodies. Antibodies against pCDK1 (sc101654), Cyclin B1 (sc245), caspase-3 (sc7148), caspase-9 (sc8355), caspase-7 (sc28295), PARP-1 (sc1561), SOD-1 (sc11407),
p-mTOR (sc 101738), NF-jB (sc109), p-NF-jB (sc101752), MMP2
(sc13594), MMP9 (sc6840) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibody against AMPK (2532S), p-AMPK (2535S), phosphorylated insulin-like growth factor-1 receptor (pIGF-1R) (3024S), AKT (9272S), pAKT (4060S), ERK1/2 (9102S), p-ERK1/2(9101S), and p-GSK-3a/b (8566S) and the HRP-conjugated secondary antibody were purchased from Cell Signaling Technology (Beverly, MA, USA). After being washed twice, the membranes were incubated with the corresponding secondary antibodies for 1 hours (dilution ratio 1:5000). Protein signals were detected with a Luminescent image analyzer (LAS-1000; Fujifilm, Tokyo, Japan).
| Caspase activity assay
Caspase-3 and -9 activities were assessed using a caspase-3 or -9 col- 
| Wound-healing motility assay
Cells were allowed to grow in a culture dish overnight and a scratch 3 mm wide was created in the monolayer using a pipette tip. After being washed twice with PBS, the cells were treated with or without HL156A, and images were captured after 24 hours. Cells were imaged in 5 random microscopic fields per well using an Olympus IX2-SLP inverted microscope (Olympus) at 9100 magnification.
| Migration assay
Cell migration was determined using a modified 2-chamber migration assay with a pore size of 8 mm. For the migration assay, cells suspended in 200 lL serum-free medium were seeded on the upper compartment of a 12-well Transwell culture chamber, and 600 lL complete medium was added to the lower compartment. After incubation at 37°C, migratory cells in the medium in the lower chamber were quantified by measuring the absorbance at optical density (OD) 595 nm.
| In vivo mice xenograft experiments
Mouse 
| Statistical analysis
All experiments were carried out at least in triplicate. Results are expressed as the mean AE standard deviation (SD). Student's t test and one-way analysis of variance (ANOVA) were used to determine the significant difference between the control and experimental groups. P-values less than .05 were considered statistically significant. 
| DISCUSSION
Previous studies suggest that metformin inhibits the proliferation and growth of various types of cancer. 3, [22] [23] [24] In addition, metformin is also associated with decreased incidence of breast, liver, pancreatic, and colorectal cancers in diabetic patients. 6, 7, 11, 12 However, the showed approximately 100-fold more potent effects compared to metformin. In a glioblastoma xenograft model, HL156A showed a comparable degree of inhibitory effect on in vivo tumor growth at the 30 mg/kg dose to that of metformin at 100 mg/kg. 16, 29 We also found that HL156A inhibits cell growth at lower concentrations (≤40 lmol/L) than metformin in oral squamous carcinoma cells. ) treated with 20 lmol/L HL156A were injected s.c. into the left flanks of male C3H mice (n = 7 per group). Tumor growth was assessed by monitoring the mass volume 2 times a week. Bodyweight was monitored and plotted against time for the HL156A (closed squares) and control groups (closed circles). Tumor volume was measured at 20 days and calculated using the formula V = (ab 2 )/2 where a was the largest diameter and b was the shortest diameter of the tumor. **P < .01 compared to untreated control. C-E, Immunohistochemistry of tumor sections. Immunohistochemistry for phosphorylated insulin-like growth factor (p-IGF), phosphorylated mammalian target of rapamycin (p-mTOR), AMP-activated protein kinase (AMPK), proliferating cell nuclear antigen (PCNA) or TUNEL was carried out on paraffin-embedded tumor sections. Graphs show the quantitative evaluation of the number of PCNA-or TUNEL-positive cells HL156A led to a reduction in mitochondrial membrane potential as well as an increase in ROS production in a time-and dose-dependent way. Furthermore, mitochondrial antioxidant proteins, such as SOD-1, were also down-regulated, but not the Nrf/Ho-1 pathway.
The imbalance between excessive ROS production and SOD-1 depletion may cause oxidative stress for oral cancer cells. This, combined with the reduction in membrane potential, resulted in the release of pro-apoptotic factors, such as cytochrome c, and the stimulation of caspases, which ultimately ends in apoptosis. 17 Our study showed that HL156A gradually increased cell apoptosis, as evidenced by the increased activity of caspase-3, -7, -9, and poly (ADPribose) polymerase (PARP).
Another important point is that HL156A exerted more potent inhibitory effects on the migration of oral cancer cells than met- Recent studies showed that IGF-1 activates two main downstream signaling pathways, the PI3K/AKT/mTOR and the Ras-Raf-MEK/ERK pathways. 32 Activation of the PI3K/AKT/mTOR pathway is known to promote cell proliferation and cell cycle progression and to reduce apoptosis, which ultimately leads to a competitive growth advantage, metastatic competence, angiogenesis, and therapy resistance. 33, 34 AKT can directly phosphorylate and activate mTOR.
mTOR plays a major role in carcinogenesis, and activation of this pathway is associated with cancer progression. 34 In the present study, HL156A was involved in mediating the antiproliferation effect . 36 The HL156A-mediated decrease in NF-jB p65 phosphorylation may be accompanied by AMPK activation. These results may suggest a role for HL156A in inhibiting the activation of NF-jB as well as in inhibition of the expression of proteins/cytokines that regulate inflammation. The importance of these signaling pathways in the pathogenesis of cancer development is suggested from a number of studies.
A recent study showed that HL156A in combination with the chemotherapeutic agent temozolomide (TMZ) inhibited the invasive properties of glioblastoma and increased the survival rate in a xenograft mouse model. 13 In our study, consistent with this, HL156A significantly reduced the growth of mouse oral squamous cell carcinoma AT84 xenograft tumors. In the immunohistochemistry assay, the number of proliferative cells was dramatically decreased, whereas the number of apoptotic cells was considerably increased.
Importantly, p-IGF-1 and p-mTOR expression were weak in control group tissues compared with HL156A-treated tumor tissues. In con- Collectively, the results of the present study suggest that HL156A may have the potential to arrest the progression of oral cancer through suppression of the IGF/AKT/mTOR pathway or MMP-2 and MMP-9 pathways. In addition, AMPK activity, at least in part, is also required for the above-mentioned tumor suppression.
In conclusion, the results clarify the beneficial effect of HL156A in reducing oral cancer development. 
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